Brain glycine levels in triazolam-treated albino rats.

Original article

English

Aburawi SM, Ahmed SS, Elhwuegi AS, Saad SF, Attia AS.

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Great Alfateh University of Medical Sciences, Tripoli, Libya. s_aburawi@hotmail.com

J Neural Transm. 2001;108(5):527-39.

Abstract

The present study investigates the effects of acute and chronic administration of triazolam in albino rats on glycine levels in different brain areas. Three experiments were conducted. In the first, five groups of rats were acutely treated with different doses of triazolam (0.25 mg/kg-4.0 mg/kg i.p.). In the second experiment, rats were treated chronically by a single daily dose of triazolam (started by 0.25 mg/kg and increased by time to 1.0 mg/kg) for 5 weeks, simulating clinical use. In the third, rats were treated chronically three daily doses of triazolam (started by 0.25 mg/kg and increased by time to 0.5 mg/kg) for 20 days, simulating a form of drug abuse. Brain levels of glycine and plasma levels of triazolam were measured using HPLC technique. The acute triazolam administration produced an increase in glycine levels in almost all brain areas studied. The chronic administration of single daily dose of triazolam produced normal glycine levels in most of the brain areas; this indicates the development of tolerance to glycine content increasing action of triazolam. The chronic administration of three daily doses of triazolam produced a decrease in glycine levels in almost all brain regions studied, which might be a prerequisite for oncoming withdrawal syndrome.

Keywords: Albino rats drug abuse glycine HPLC tolerance triazolam.

Link/DOI: http://www.springerlink.com/content/wkl1ybqkkb6jr1k6/